Human Genome Sciences (HGSI) says the FDA has denied its bid to gain an approval for its anthrax drug, asking for additional information on raxibacumab in a complete response letter. The delay is not a big surprise, given the recent vote by an advisory council to request more data on what benefits the drug provides beyond antibiotics. And the news hardly dented HGS stock in premarket trading; the company has been one of the hottest in the biotech sphere as investors thrilled to the news of the developer's progress with a new lupus drug. Report